Medicines Co. (MDCO) Announces Presentation of Significant Data from MDCO-216 Phase 1 on HDL Particles
Tweet Send to a Friend
Medicines Co. (NASDAQ: MDCO) presented the results of a Phase 1 study for MDCO-216 that showed that the drug had ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
